Needham & Company LLC Reaffirms Buy Rating for Heron Therapeutics (NASDAQ:HRTX)

Needham & Company LLC reaffirmed their buy rating on shares of Heron Therapeutics (NASDAQ:HRTXFree Report) in a report released on Thursday, Benzinga reports. Needham & Company LLC currently has a $5.00 price target on the biotechnology company’s stock.

Separately, Capital One Financial initiated coverage on shares of Heron Therapeutics in a report on Tuesday, April 23rd. They set an overweight rating and a $6.00 target price for the company.

Read Our Latest Analysis on HRTX

Heron Therapeutics Price Performance

Shares of HRTX stock opened at $3.20 on Thursday. The stock has a market cap of $482.08 million, a P/E ratio of -5.25 and a beta of 1.73. The stock has a fifty day moving average price of $2.78 and a 200 day moving average price of $2.20. Heron Therapeutics has a one year low of $0.50 and a one year high of $3.29.

Heron Therapeutics (NASDAQ:HRTXGet Free Report) last released its quarterly earnings data on Tuesday, March 12th. The biotechnology company reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.15) by $0.08. The company had revenue of $34.23 million during the quarter, compared to the consensus estimate of $30.98 million. Equities research analysts anticipate that Heron Therapeutics will post -0.14 EPS for the current year.

Institutional Investors Weigh In On Heron Therapeutics

Several large investors have recently modified their holdings of HRTX. SG Americas Securities LLC acquired a new position in shares of Heron Therapeutics in the third quarter valued at approximately $31,000. Commonwealth Equity Services LLC lifted its position in Heron Therapeutics by 5.5% in the 3rd quarter. Commonwealth Equity Services LLC now owns 314,826 shares of the biotechnology company’s stock valued at $324,000 after acquiring an additional 16,467 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in Heron Therapeutics by 5.8% in the 3rd quarter. Bank of New York Mellon Corp now owns 353,395 shares of the biotechnology company’s stock worth $364,000 after purchasing an additional 19,345 shares during the period. Richmond Brothers Inc. increased its holdings in Heron Therapeutics by 142.9% during the 3rd quarter. Richmond Brothers Inc. now owns 103,009 shares of the biotechnology company’s stock worth $106,000 after purchasing an additional 60,604 shares in the last quarter. Finally, Monaco Asset Management SAM increased its holdings in Heron Therapeutics by 72.1% during the 3rd quarter. Monaco Asset Management SAM now owns 696,908 shares of the biotechnology company’s stock worth $718,000 after purchasing an additional 291,908 shares in the last quarter. 80.01% of the stock is currently owned by institutional investors.

Heron Therapeutics Company Profile

(Get Free Report)

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.

See Also

Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.